Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global,...

Related Keywords

China ,Sweden ,United States ,Stockholm ,United Kingdom ,Switzerland ,American ,Marie Galay ,Villa Baca ,Exchange Commission ,Kidney International ,European Commission ,Nefigard Topline ,Full Prescribing Information ,Primary Immunoglobulin ,Nasdaq Stockholm ,American Depositary Shares ,Nasdaq Global Select Market ,Private Securities Litigation Reform Act ,Calliditas Therapeutics ,Life Expectancy ,Patients From ,Southeastern United States With Iga ,Kidney Int Rep ,Nefigard Trial Investigators ,Why Target ,Treat Iga ,Iga Nephropathy ,Nationwide Population Based Cohort ,Health Care Amp Hospitals ,Pharmaceuticals ,Medical Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,